Document is current
Any future updates will be listed below
-
Authors
Esfahani, Mohammad Shahrokh
Hamilton, Emily G.
Mehrmohamadi, Mahya
Nabet, Barzin Y. https://orcid.org/0000-0002-4824-3533
Alig, Stefan K. https://orcid.org/0000-0001-6825-702X
King, Daniel A.
Steen, Chloé B. https://orcid.org/0000-0001-7290-7128
Macaulay, Charles W.
Schultz, Andre https://orcid.org/0000-0002-2909-3154
Nesselbush, Monica C.
Soo, Joanne
Schroers-Martin, Joseph G. https://orcid.org/0000-0003-4128-2537
Chen, Binbin https://orcid.org/0000-0003-2973-2718
Binkley, Michael S.
Stehr, Henning
Chabon, Jacob J. https://orcid.org/0000-0003-1820-9737
Sworder, Brian J.
Hui, Angela B-Y
Frank, Matthew J.
Moding, Everett J. https://orcid.org/0000-0001-7913-5351
Liu, Chih Long
Newman, Aaron M. https://orcid.org/0000-0002-1857-8172
Isbell, James M. https://orcid.org/0000-0002-7305-876X
Rudin, Charles M.
Li, Bob T.
Kurtz, David M. https://orcid.org/0000-0002-6382-4651
Diehn, Maximilian https://orcid.org/0000-0003-2032-0581
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
- License Information
-
More Information
Article History
Received: 22 February 2021
Accepted: 14 January 2022
First Online: 31 March 2022
Competing interests
: A.A.A. reports research funding from Celgene, Pfizer, ownership interests in FortySeven, CiberMed, ForeSight and paid consultancy from Roche, Genentech, Janssen, Pharmacyclics, Gilead, Celgene and Chugai. M.D. reports research funding from Varian Medical Systems and Illumina, ownership interest in CiberMed, ForeSight and paid consultancy from Roche, AstraZeneca, Illumina, RefleXion and BioNTech. J.J.C. reports paid consultancy from Lexent Bio Inc. and ownership interests in ForeSight. A.M.N. has patent filings related to expression deconvolution and cancer biomarkers and has served as a consultant for Roche, Merck and CiberMed. D.M.K. reports paid consultancy from Roche. B.T.L. has served as an uncompensated advisor and consultant to Amgen, Genentech, Boehringer Ingelheim, Lilly, AstraZeneca and Daiichi Sankyo. B.T.L. reports receiving research grants to his institution from Amgen, Genentech, AstraZeneca, Daiichi Sankyo, Lilly, Illumina, GRAIL, Guardant Health, Hengrui Therapeutics, MORE Health and Bolt Biotherapeutics. B.T.L. has received academic travel support from MORE Health and Jiangsu Hengrui Medicine. B.T.L. reports to be inventor on two institutional patents at MSKCC (US62/685,057, US62/514,661) and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. J.M.I. reports serving as an unpaid consultant to Amgen and Roche-Genentech, institutional research support from Guardant Health and GRAIL, and ownership interest in LumaCyte. A.A.A., M.D., M.S.E., D.M.K., J.J.C., and B.Y.N. report patent filings related to cancer biomarkers. M.S.E., M.M., A.A.A. and M.D. have patent filing related to this paper. B.Y.N. is currently an employee and holds stock from Roche/Genentech. The remaining authors declare no competing interests.
